In a quiet room, some individuals perceive ringing, buzzing, or a high-pitched whine that others cannot detect. This sound persists regardless of attempts to block it or to sleep. For many, it is a constant presence.
This is tinnitus: the perception of a phantom sound with no external source. It affects roughly 10 to 15% of the global population, making it one of the most prevalent neurological conditions in the world. And despite its staggering reach, science has struggled to explain exactly how or why the brain generates it.
A major study published in PNAS (2026) by researchers at Anhui University and Oregon Health and Science University identified a specific brain circuit involving the neurotransmitter serotonin that can directly induce tinnitus-like behaviour in mice. Notably, silencing this circuit led to significant improvement in tinnitus symptoms.
This represents one of the most precise circuit-level explanations for tinnitus to date.
Serotonin: Beyond Mood Regulation
Serotonin is commonly recognised as the “feel-good” chemical targeted by antidepressants such as selective serotonin reuptake inhibitors (SSRIs). However, serotonin functions beyond mood regulation. It is widely distributed throughout the brain and contributes to sleep, cognition, sensory processing, and, as recent research demonstrates, auditory perception.
The association between serotonin and tinnitus has been suggested for years. Clinical observations indicated that some patients with tinnitus exhibited abnormal serotonin signalling. Additionally, some individuals prescribed SSRIs reported a worsening of tinnitus symptoms, despite these medications being intended to improve mood. Until recently, the precise circuit-level mechanism underlying this connection remained unexplained.
Mapping the Circuit: From the Dorsal Raphe Nucleus to the Auditory Brain Region
The dorsal raphe nucleus (DRN) is a small cluster of cells located deep within the brainstem. It produces a significant portion of the brain’s serotonin and distributes it to various regions throughout the nervous system.
The researchers identified the dorsal cochlear nucleus (DCN) as one of the DRN’s target regions. The DCN processes auditory information and has long been considered a key site for tinnitus generation. It serves as the brain’s initial major processing hub for auditory signals from the ear. When its principal cells, known as fusiform cells, exhibit abnormally rapid firing in the absence of sound input, the brain interprets this electrical activity as sound, resulting in tinnitus.
The research team employed advanced techniques, including retrograde tracing, genetic viral tools, optogenetics, and chemogenetics, to map a specific subpopulation of serotonin neurons in the DRN that project directly to the DCN. This pathway was designated as the 5-HT DRN→DCN circuit.
The caudal (rear) portion of the DRN accounted for approximately 66.5% of serotonin-producing neurons projecting to the DCN, establishing it as the primary source of serotonergic input to this auditory region.
Modulating Tinnitus: Activation and Inhibition
With this circuit identified, the researchers conducted a series of experiments to determine whether activating it could induce tinnitus and whether inhibiting it could alleviate the condition.
Optogenetic activation: The researchers expressed the light-sensitive protein channelrhodopsin in DRN serotonin neurons projecting to the DCN. When blue light at 20 Hz was applied to the DRN in awake mice, fusiform cells in the DCN exhibited increased firing rates, producing the electrical hyperactivity associated with tinnitus.
Chemogenetic activation: The team utilised chemogenetics, expressing a modified receptor in specific neurons and using a designer drug to selectively activate the DRN→DCN serotonin circuit. Following activation, mice developed measurable tinnitus-related behaviour within one week. The gap-prepulse inhibition of the acoustic startle reflex (GPIAS), a standard behavioural test for tinnitus in rodents, indicated that the mice could no longer detect brief silences in background noise, suggesting the perception of a phantom sound. Importantly, their hearing thresholds remained normal, confirming the presence of tinnitus rather than hearing loss.
Upon withdrawal of the drug, the tinnitus-related behaviour reversed within three days, demonstrating that the circuit’s effects were dynamic and reversible rather than permanently damaging.
Receptor blockade: The researchers investigated the specific serotonin receptor involved by administering a selective 5-HT2A receptor blocker (MDL-11939) prior to circuit activation. This intervention reduced the incidence of tinnitus in mice from 83% to 17%. The 5-HT2A receptor, known to mediate serotonin’s excitatory effects on DCN fusiform cells, appears to be the critical mediator through which this circuit generates tinnitus.
The Relationship Between Noise Exposure and Tinnitus
Noise exposure is the most common cause of tinnitus in humans. The research team wanted to know whether the DRN→DCN serotonin circuit plays a role in this real-world scenario.
The researchers exposed mice to loud noise (116 dB, comparable to the level at a close-range rock concert) and, within the DCN, used an advanced serotonin sensor capable of detecting real-time serotonin release in freely moving animals.
Following noise exposure, serotonin levels in the DCN increased and remained elevated, coinciding with the onset of tinnitus-related behavior. Concurrently, DRN serotonin neurons projecting to the DCN exhibited significantly increased activity, as measured by calcium imaging techniques that track neuronal firing in real time via fibre-optic implants.
These findings suggest that noise exposure not only damages the inner ear but also triggers a serotonin response in the brain, which amplifies abnormal auditory system activity and may sustain or generate tinnitus at the neural level.
When the researchers chemogenetically silenced the DRN→DCN circuit in mice with established noise-induced tinnitus, tinnitus-related behaviour was significantly reduced. In the treatment group, only 42.9% of mice retained tinnitus behaviour following circuit inhibition, compared to 100% in the control group.
Implications for SSRI Users
A key clinical insight from this research pertains to antidepressants. SSRIs function by inhibiting serotonin reuptake at synapses, thereby increasing serotonin signalling throughout the brain, including in the auditory circuit connecting the DRN to the DCN, as this study suggests.
The researchers observed that acute administration of citalopram, a commonly prescribed SSRI, was sufficient to induce tinnitus-related behaviour in mice. This finding offers a plausible neurological explanation for why some patients, particularly those sensitive to elevated serotonin levels or prescribed higher doses, report new or worsened tinnitus following SSRI initiation.
These findings do not suggest discontinuing or avoiding SSRIs, which remain essential medications for many individuals. However, they indicate that tinnitus as a side effect of serotonergic drugs may be mechanistically predictable and potentially preventable with targeted interventions.
A Revised Framework for Understanding Tinnitus
This research is significant because it reframes tinnitus, at least in some cases, as a dynamic, neuromodulator-driven state rather than a permanent structural disorder. Excess serotonin, or serotonin acting within specific neural circuits, appears to function as a pathological switch that reconfigures the auditory system into an overactive state, which the brain misinterprets as sound.
This mechanism is conceptually analogous to processes in the brain’s emotional circuits. Elevated serotonin in the amygdala, the brain’s fear centre, promotes anxiety, while elevated serotonin in the DCN, as suggested by this research, promotes phantom sound perception. Thus, the same neurotransmitter can produce different disorders depending on its neural targets.
These findings present new possibilities for treatment. Instead of using broad-spectrum drugs, future therapies may focus on modulating the DRN→DCN circuit specifically, employing 5-HT2A receptor antagonists or other circuit-targeted approaches to reduce hyperactivity in the auditory system without affecting broader brain function.
Conclusion
Tinnitus has long been a challenging medical condition, perceptible only to those affected and resistant to treatment. While this research does not provide a cure, it identifies a precise, modifiable brain circuit that can initiate and suppress tinnitus.
The DRN→DCN serotonin pathway, a previously underrecognized connection between the brain’s emotional regulation system and its auditory processing hub, appears to play a central role in the generation of tinnitus. Understanding this pathway provides a foundation for developing targeted therapies for one of the most common and undertreated neurological conditions.
For the millions affected by persistent tinnitus, these findings represent a meaningful advancement.
Reference
Yu, M.-T., Dai, Z.-Y., Wang, S.-X., Wang, K.-J., Qin, C.-H., Zhou, Y.-M., Guo, X.-T., Pan, C.-C., Sun, J.-Q., Sun, J.-W., Chen, W.-H., Jin, Y., Wu, Q.-W., Trussell, L.O., & Tang, Z.-Q. (2026). A discrete serotonergic circuit is involved in the generation of tinnitus behaviour. PNAS, 123(17), e2509692123. https://doi.org/10.1073/pnas.2509692123